Applications and therapeutic areas of Capmatinib

Capmatinib is a small molecule kinase inhibitor targeting c-Met. Capmatinib is indicated for the treatment of patients with non-small cell lung cancer whose tumors have mutations leading to mesenchymal epithelial transition (MET) exon 14 skipping.

Over the past decade, molecular characterization of NSCLC has revealed numerous oncogenic driver events in NSCLC that have led to several highly effective therapies. Although small-molecule inhibition ofMETsignaling is a promising goal, it has proven difficult. Capmatinib is a specific methotrexate inhibitor. received accelerated approval from the U.S. Food and Drug Administration (FDA) in 2020 for the treatment of non-small cell lung cancer carrying methotrexate exon 14 skipping mutations. As a first-line therapy, 68% of patients in phase II clinical trials responded to capmatinib, with a median duration of 12.6 months and a controllable safety profile. Although FDA approval is currently limited to METexon14 skipping mutations, capmatinib has shown potential in other subpopulations of METdysregulated non-small cell lung cancer and is currently being studied. This review covers the preclinical and early clinical data leading to the approval of capmatinib, discusses the management of treatment-related toxicities, and provides potential avenues for further research. There are generic drugs that are officially on the market in Laos, and each box costs about 3 about 3,000. If you want to get more high-quality information, you can contact YaDE. YaDE will do its best to learn more about high-quality overseas drugs for you.

xa0